Sirnaomics Ltd
HKEX:2257
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sirnaomics Ltd
EPS (Diluted)
Sirnaomics Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sirnaomics Ltd
HKEX:2257
|
EPS (Diluted)
$0
|
CAGR 3-Years
49%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Sirnaomics Ltd
Glance View
Sirnaomics Ltd. operates as a holding company. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2021-12-30. The firm is engaged in discovering and developing drugs for indications with unmet medical needs and market opportunities. The Company’s product pipeline has broad therapeutic utility across market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. The Company’s targets once selected based on clear scientific rationale, it applies an algorithm based on its understanding of the biochemical mechanisms involved in RNA interference to identify candidate RNA interference (RNAi) trigger sequences against the selected target gene and employ high throughput processes to design, screen and test future pipeline products. The company has five ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in investigational new drug (IND) enabling or advanced preclinical studies.
See Also
What is Sirnaomics Ltd's EPS (Diluted)?
EPS (Diluted)
-0.2
USD
Based on the financial report for Dec 31, 2025, Sirnaomics Ltd's EPS (Diluted) amounts to -0.2 USD.
What is Sirnaomics Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
21%
Over the last year, the EPS (Diluted) growth was 77%. The average annual EPS (Diluted) growth rates for Sirnaomics Ltd have been 49% over the past three years , 21% over the past five years .
